GLP-1 agonists for type 2 diabetes: Pharmacokinetic and toxicological considerations

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 1, 2013, Pages 17-29

  Jespersen, Maria J ^a   Knop, Filip K ^a   Christensen, Mikkel ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Exenatide; Glucagon like peptide 1 (GLP 1); Incretin mimetics; Liraglutide; Pharmacokinetics; Safety; Type 2 diabetes

Indexed keywords

ATORVASTATIN; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GRISEOFULVIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LISINOPRIL; METFORMIN; MEVINOLIN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; WARFARIN;

ACUTE HEMORRHAGIC PANCREATITIS; ADD ON THERAPY; ANTIBODY TITER; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CONSTIPATION; DIARRHEA; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME DEGRADATION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART RATE; HEMORRHAGIC PANCREATITIS; HUMAN; HYPOGLYCEMIA; INJECTION SITE NODULE; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PROSTATE CANCER; PROTEIN SECRETION; REVIEW; SIDE EFFECT; STOMACH EMPTYING; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PANCREATITIS; PEPTIDES; TACHYPHYLAXIS; VENOMS;

EID: 84871238486     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.731394     Document Type: Review

References (92)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87(4):1409-39 (Pubitemid 350041474)
2. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
3. Shyangdan DS, Royle PL, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010;10:20
4. Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep 2010;10(2):124-32
5. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57(3):678-87
6. Hare KJ, Knop FK. Incretin-based therapy and type 2 diabetes. Vitam Horm 2010;84:389-413
7. Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003;114(2-3):189-96 (Pubitemid 36773884)
8. Reimann F, Gribble FM. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002;51(9):2757-63 (Pubitemid 34970929)
9. Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003;52(5):1147-54 (Pubitemid 36523349)
10. Tolhurst G, Reimann F, Gribble FM. Intestinal sensing of nutrients. Handb Exp Pharmacol 2012;209:309-35
11. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10(3):167-77
12. Carr RD, Larsen MO, Winzell MS, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 2008;295(4):E779-84
13. Thondam SK, Cross A, Cuthbertson DJ, et al. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. Diabet Med 2012;29(8):e205-10
14. Imeryuz N, Yegen BC, Bozkurt A, et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997;273(4 Pt 1):G920-7
15. Herrmann-Rinke C, Voge A, Hess M, Goke B. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol 1995;147(1):25-31
16. Dube PE, Brubaker PL. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res 2004;36(11-12):755-60 (Pubitemid 40115895)
17. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003;52(2):380-6 (Pubitemid 36173193)
18. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50(3):609-13 (Pubitemid 32195226)
19. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of theimpaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86(8):3717-23 (Pubitemid 32755966)
20. Nauck MA, Vardarli I, Deacon CF,et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;54(1):10-18
21. Calanna S, Gluud LL, Holst JJ, et al. Glucagon-Like Peptide-1 in Patients with Type 2 Diabetes Mellitus - Systematic Review and Meta-analysis of Clinical Studies. ADA; 2012
22. Mentlein R, Dipeptidyl-peptidase IV. CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85(1):9-24 (Pubitemid 29505281)
23. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44(9):1126-31
24. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136(8):3585-96
25. Hupe-Sodmann K, Goke R, Goke B, et al. Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides 1997;18(5):625-32 (Pubitemid 27319773)
26. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005;48(9):1882-90 (Pubitemid 41317844)
27. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide- 1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999;140(11):5356-63
28. Deacon CF, Pridal L, Klarskov L, et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996;271(3 Pt 1):E458-64
29. Carone FA, Peterson DR, Flouret G. Renal tubular processing of small peptide hormones. J Lab Clin Med 1982;100(1):1-14 (Pubitemid 12054893)
30. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005;128(2):117-24 (Pubitemid 40380912)
31. Rachman J, Gribble FM, Barrow BA, et al. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 1996;45(11):1524-30 (Pubitemid 26357544)
32. Zander M Madsbad S Madsen JL Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control insulin sensitivity beta-cell function in type 2 diabetes a Parallel-group Study. Lancet 2002;359(9309)824-30 (Pubitemid 34233752)
33. Vilsboll T, Toft-Nielsen MB, Krarup T, et al. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000;23(6):807-12 (Pubitemid 30414198)
34. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995;38(6):720-5
35. Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996;45(6):832-5 (Pubitemid 26168585)
36. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006;49(2):253-60 (Pubitemid 43185393)
37. Thorens B, Porret A, Buhler L, et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993;42(11):1678-82 (Pubitemid 23318127)
38. Assessment report for Byetta. European Medicines Agency; 2010
39. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energyintake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281(1):E155-61
40. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62(2):173-81 (Pubitemid 40674548)
41. Copley K, McCowen K, Hiles R, et al. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006;7(4):367-74
42. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64(3):317-27 (Pubitemid 47283860)
43. Blase E, Taylor K, Gao HY, et al. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 2005;45(5):570-7 (Pubitemid 40562948)
44. Kothare PA, Linnebjerg H, Skrivanek Z, et al. Exenatide effects on statin pharmacokinetics and lipid response.Int J Clin Pharmacol Ther 2007;45(2):114-20 (Pubitemid 46344143)
45. Linnebjerg H, Kothare P, Park S, et al. The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics n patients with hypertension. Int J Clin Pharmacol Ther 2009;47(11):651-8
46. Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol 2005;45(9):1032-7 (Pubitemid 41192362)
47. Soon D, Kothare PA, Linnebjerg H, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 2006;46(10):1179-87 (Pubitemid 44387418)
48. Norris SL, Lee N, Thakurta S, Chan BK. Exenatide efficacy and safety: a systematic review. Diabet Med 2009;26(9):837-46
49. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 2011;27(6):528-42
50. Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.Diabetes Metab Res Rev2004;20(5):411-17 (Pubitemid 39302967)
51. Macconell L, Brown C, Gurney K, Han J. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012;5:29-41
52. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141(1):150-6
53. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care2009;32(5):834-8
54. Spranger J, Gundert-Remy U, Stammschulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology 2011;141(1):20-3
55. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33(11):2349-54
56. Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KrasG12D mouse model. Diabetes 2012;61(5):1250-62
57. Gale EA. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat? Diabetes 2012;61(5):986-8
58. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011;96(6):1695-702
59. Mendis B, Simpson E, Macdonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 2012;74(3):437-44
60. Nauman J, Janszky I, Vatten LJ, Wisloff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011;306(23):2579-87
61. Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011;10:22
62. Assessment report for Bydureon. 2012
63. Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet2011;50(1):65-74
64. Drucker DJ Buse JB Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes a Randomised Open-label Non-inferiority Study. Lancet 2008;372(9645)1240-50
65. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376(9739):431-9
66. Diamant M, Van GL, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012;35(4):683-9
67. Assessment report for Victoza. European Medicines Agency; 2009
68. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25(8):1398-404 (Pubitemid 41071152)
69. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45(2):195-202 (Pubitemid 34208381)
70. Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010;38(11):1944-53
71. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68(6):898-905
72. Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with liraglutide-a once-daily GLP-1 analog-does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol 2011;51(12):1696-703
73. Zdravkovic M, Ekblom M, Brøndsted L, et al. The effect of liraglutide on the absorption pharmacokinetics of concomitant oral drugs with different solubility and permeability properties in healthy subjects. Diabetologia 2008;51(Suppl 1):S890
74. Jelsing J, Vrang N, Hansen G, et al. Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight. Diabetes Obes Metab2012;14(6):531-8
75. Morrow L, Hompesch M, Guthrie H, et al. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab 2011;13(1):75-80
76. Garber A, Henry R, Ratner R, et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD- 3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-81
77. Nauck M, Frid A, Hermansen K, et al Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32(1):84-90
78. Russell-Jones D, Vaag A, Schmitz O,et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52(10):2046-55
79. Buse JB, Rosenstock J, Sesti G, et al.Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374(9683):39-47
80. Bjerre KL, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151(4):1473-86
81. Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011;96(3):853-60
82. Endocrine and Metabolic Drug Advisory Committee. Liraglutide (injection) for the Treatment of Patients with Type 2 Diabetes NDA 22-34 Briefing Document. 2009
83. Nyborg NC, Molck AM, Madsen LW, Bjerre KL. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61(5):1243-9
84. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26(3):268-78
85. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32(7):1224-30
86. Marso SP, Lindsey JB, Stolker JM, et al.Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011;8(3):237-40
87. Christensen M, Bagger JI, Vilsboll T, Knop FK. The alpha-cell as target for type 2 diabetes therapy. Rev Diabet Stud 2011;8(3):369-81
88. Gallwitz B, Anorexigenic effects of GLP- 1 and Its analogues. Handb Exp Pharmacol 2012;209:185-207
89. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36(6):843-54
90. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function. Diabetes2011;60(5):1599-607
91. Buse JB, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. EASD 47th Annual Meeting; 14 September 2011
92. GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes. 16-112011.